The estimation of endogenous tumor necrosis factor alpha and cortisol levels in serum in advanced neoplasm

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 2, 1999, Pages 241-245

  Baranowski, M ^a   Muc Wierzgon M ^a,c   Madej, K ^a   Wierzgon J ^b   Zubelewicz, B ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Dept of Surgery   (Poland)

^c 5th Department of Internal Medicine   (Poland)

Author keywords

Advanced neoplasm; Circadian rhythm; Cortisol level; Endogenous TNF alpha

Indexed keywords

ANTINEOPLASTIC AGENT; HYDROCORTISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; MALE; NEUROENDOCRINOLOGY; PANCREAS CARCINOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; STEROID ANALYSIS; STOMACH CARCINOMA;

AGED; CARCINOMA; CIRCADIAN RHYTHM; COLORECTAL NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032812992     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Aggarwal B.B., Natarajan K.: Tumor necrosis factor : Developments during the last decade. Eur. Cytokine Netw. 7, 2 : 93 - 124, 1996.
2. Bernardini R., Calogero A.E.: Hypothalamus - pituitary -adrenal axis activity during the inflammatory / immune response. Horizons in Endocrinology. Raven Press, NY 50 : 197-227, 1989.
3. Bernardini R.: Interaction between tumor necrosis factor alpha, hypothalamic corticotropin releasing hormone and adrenocorticotropic secretion in rats. Endocrinology 6, 126, 2876-2884,1990.
4. Bertini R.M., Bianchi M., Ghezzi P.: Adrenalectomy sensitizes mice to the letal effects of Interleukin-1 and tumor necrosis factor. J. Exp. Med. 167: 1708-1711, 1988.
5. Beutler B., Krochin N., Milsark C.: Control of cachectin synthesis: mechanisms of endotoxin resistance. Science 232: 977-981, 1986.
6. Clarke B., Bost L.: Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J. Immunol. 143 : 464-468, 1989.
7. Endres S, Fulle B, Sinha D, Stoll C : Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor alpha and interleukin - 1 beta by mononuclear cells. Immunology 72:56-59, 1991.
8. Hawes A.S., Rock C.V., Lowry S.F., Calvano S.E.: In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine response to Escherichia coli endotoxin. Infect. Immun. 60: 2641-2646, 1992.
9. Fantuzzi G., Ghezzi P.: Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases. Mediat. Inflamm. 2, 263-266, 1993.
10. Fantuzzi G., Di Santo E., Benigni F.: Role of the Hypothalamus - Pituitary - Adrenal Axis in the Regulation of TNF production in mice. J Immunol. 3552-3555, 1995.
11. Hichs D.G., Gokan T., O'Keefe R.J., Totterman S.M., Fultz P.J.: Primary lymphoma of bone. Correlation of magnetic resonance imagin features with cytokine production by tumor cells. Cancer Feb. 75(4) : 973-980, 1992.
12. Jaatela M.: TNF α potent inhibitor of adrenocorticotropin induced cortisol production and steroidogenic P-450 enzyme expression in cultured human fetal adrenal cells. Endocrinology 1, 128:623-627:1991.
13. Lazar G., Agganval M.K.: The influence of a novel glucocorticoid antagonist on endotoxin lethality in mice strains. Biochem. Med. Metab. Biol. 36: 70-74, 1986.
14. Madej K., Muc M., Wierzgoń J.: Circadian variation of endogenous TNF alpha plasma level in patients with pancreatic cancer. 10th Mediterranean Congress of Chemotherapy, Antalaya. Ed ; Monduzzi Editore, Bologna 549-552, 1996.
15. Muc M., Baranowski M., Madej K.: Tumor necrosis factor in advanced gastrointestinal neoplasms. Haematologia Vol. 27, 2: 85-92, 1996.
16. Muc M., Madej K., Baranowski M.: Fluctuation of endogenous TNF alpha concentration in plasma in advanced cancer patients. J. of Biol. Reg. and Hom. Agents. Vol. 10, 1: 25-26,1996.
17. Muc M., Madej K., Baranowski M.: Diurnal rhythmicity of endogenous TNF α concentration in plasma of advanced cancer. Oncol. Repp. 4(3): 637-640, 1997.
18. Parant M., Le Contel C., Parant F.: Influence of endogenous glucocorticoid on endotoxin-induced production of circulating TNF alpha. Lymphokine Cytokine Res. 10: 265-269, 1991.
19. Reincke M.: Impairment of adrenocortical function associated with increased plasma TNF alpha and IL-6 concentration in african Trypanosomiasis, Neuroimm. 1, 1-1,1991.
20. Rollof J.: Are TNF alpha or cortisol of value of the diagnosis of acute septicaemia. Scand. J. Infect. Dis. 22, 507-512, 1992.
21. Sauerwein H.P.: Cytokines and metabolic changes. Cytokine Res. 2, 6-15, 1992.
22. Schlening M., Munker R.: Tumor necrosis factor: An update on basic research and clinical applications. Klin Wochenschr. 68, 841-846, 1990.
23. Smolensky M.H., Halberg F., Sargent F.S.: Chronobiology of the life sequence. In: Advances in Climatic Physiology. S.L.K. Ogata and H. Yoshimura. Eds. Igaku Shoin Tokyo: 281-319, 1972.
24. Tannenbaum C.S., Hamilton T.A.: Lipopolisaccharide-induced gene expression in murine peritoneal macrophages is selectively supressed by agents that elevate intracellular cAMP. J. Immunol. 142: 1274-1278, 1989.
25. Zieleniewski W., Mickowicz A., Kudowicz J.: The adrenal cortex function in patients with acquired immunodeficiency syndrome. Przegl. Lek. 3-4, 106-110, 1993.